Acute myeloid leukaemia (AML): Treatment of the older patient

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 1, 2001, Pages 139-151

  Büchner, Thomas ^a   Hiddemann, Wolfgang ^b   Schoch, Claudia ^b   Haferlach, Torsten ^b   Sauerland, Maria Cristina ^c   Heinecke, Achim ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

AML; Daunorubicin dosage; Growth factors; Maintenance treatment; Older patient; Prognostic factors

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY; DOSE RESPONSE; DRUG MEGADOSE; ELDERLY CARE; FEVER; FLUID RETENTION; GRANULOCYTE TRANSFUSION; HUMAN; HYPOTENSION; KARYOTYPE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035027285     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2000.0120     Document Type: Article

References (55)

1. The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome
2. AML associated with previous cytotoxic therapy. MDS or myelo-proliferative disorders: Results from the MRC's 9th AML trial
3. Second International Workshop on Chromosomes in Leukemia: General Report
4. Annotation: Chromosome changes in acute leukaemia
5. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia
6. Fourth International Workshop on Chromosomes in Leukemia. Clinical significance of chromosomal abnormalities in acute non-lymphoblastic leukemia
7. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
8. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia
9. Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on chromosomes in leukemia
10. Prognostic significance of karyotype in de novo adult acute myeloid leukemia
11. High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia
12. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia
13. Meeting report: 1st International Conference on reversal of multidrug resistance in cancer
14. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
15. Treatment of acute myeloid leukemia: A study by Cancer and Leukemia Group B
16. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
17. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group
18. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
19. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study
20. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B
21. Intensive postremission chemotherapy in adults with acute myeloid leukemia
22. Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study
23. 2 improves response and survival in elderly patients with AML
24. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML Cooperative Group
25. One single course of sequential high dose AraC/mitoxantrone (S-HAM) has the same long-term effect as three years of maintenance in AML patients after TAD-HAM double induction. Randomized trial by the German AMLCG
26. Age and sex distributions of hematological malignancies in the U.K
27. A randomized comparison of postremission therapy in acute myelogenous leukemia. A Southeastern Cancer Study Group trial
28. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study
29. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
30. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10)
31. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy of acute myeloid leukaemia in first remission: Results of MRC AML 10 trial
32. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: A report of the Italian Cooperative Group GIMEMA
33. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia
34. Aclarubixin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia
35. Varying intensity of postremission therapy in acute myeloid leukemia
36. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
37. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Study Group
38. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
39. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogeous leukemia in elderly patients
40. Superior CR rates with DAT induction compared to ADE or MAC in older patients with AML, but three additional courses of consolidation chemotherapy and maintenance with interferon do not improve survival: Trial
41. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy
42. On the value of intensive remission-induction chemotherapy in the elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group
43. Full dose versus attenuated dose daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly
44. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly
45. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients. A randomized comparison with 5-day TAD
46. - cases
47. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkable distinct response to standard chemotherapy. A Southwest Oncology Group study
48. Management of acute myeloid leukemia in elderly patients
49. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse
50. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML)
51. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients
52. IL-II, pleiotropic cytokine: Exciting new effects of IL-II on gastrointestinal mucosal biology
53. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti CD33 calicheamicin immunoconjugate
54. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) Study
55. Successful nonmyeloablative allogeneic hematopoietic stem cell transplantation in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis